Enzyme Linked Immunosorbent Assay (ELISA) News and Research

RSS

SARS-CoV-2 Delta and Delta AY.1 variant show similar Covaxin-induced neutralization

A new study from India suggests that the Indian-made Covaxin whole-virus inactivated vaccine against the SARS-CoV-2 retains significant efficacy against the newer delta variants of the virus.

3 Aug 2021

Scientists develop a potent peptide inhibitor of SARS-CoV-2 in vitro

In a recently published article in the journal Drugs in R&D, scientists have described the development and validation of a 13-amino acid peptide inhibitor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

2 Aug 2021

An assay capable of detecting SARS-CoV-2 antibodies in breast milk and other samples

In a recent study by US researchers (currently available on the medRxiv* preprint server), a specific immunoassay based on the spike glycoprotein’s receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is not only well suited for the detection of antibody response after infection and vaccination but may also represent a method of choice when conducting seroepidemiological studies.

19 Jul 2021

Rapid COVID-19 antibody detection with time‐resolved fluorescence immunoassay

A new study published in the journal Biotechnology and Applied Biochemistry deals with the development of a time-resolved fluorescence immunoassay (TRFIA) for the detection of total COVID-19 antibodies in humans.

15 Jul 2021

SARS-CoV-2 antibody testing in oral fluids may be an efficient way forward for research in children

A recent study by researchers from the United Kingdom (UK) and Brazil shows how laboratory assays based on the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies in oral fluids can be used as a suitable tool for population-based seroepidemiology studies in children. The paper is currently available on the medRxiv* preprint server while it undergoes peer review.

8 Jul 2021

Breakthrough SARS-CoV-2 infection among fully vaccinated likely to be less transmissible

Researchers in the United States have conducted a study suggesting that individuals fully vaccinated against coronavirus disease 2019 (COVID-19) who develop breakthrough infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are less likely to transmit the virus to others than unvaccinated infected individuals.

8 Jul 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

Novel biosensor offers rapid quantitative variant of concern-independent serology for SARS-CoV-2

Even as herculean efforts are being made to extend the reach of vaccination against COVID-19 to all the regions of the world, there is a dire need for rapid and sensitive tests to assess the antibody response to the various vaccines used and to monitor antibody titers over time. A new preprint describes a new approach to this problem which could be applied to other molecules of interest as well, both in laboratories and at the point of care.

25 Jun 2021

Does SARS-CoV-2 alter the expression of molecules involved in the homeostasis of blood pressure?

A recent study finds that COVID-19 alters the expression of several molecules involved in the homeostasis of blood pressure.

22 Jun 2021

Study shows a robust immune response to COVID-19 vaccine in breastfeeding health workers

A recent study by researchers from Poland, published in the journal Vaccines, shows how levels of IgA and IgG antibodies specific to the spike glycoprotein of SARS-CoV-2 increase in both breast milk and serum samples of mothers following vaccination against COVID-19 – with important implications for further vaccine planning endeavors.

21 Jun 2021

Study shows that COVID-19 was present in five U.S. states in December 2019, even before the first reported case in China

In a recent study, a group of researchers aimed to identify exactly how early SARS-CoV-2 was circulating throughout the United States.

21 Jun 2021

Indian WHO study examines COVID-19 susceptibility in children versus adults

Now, a group of researchers from India have explored this concept due to the lack of solid evidence and have undertaken a community and population-based serosurveillance study for the coronavirus infection under the World Health Organisation (WHO) Unity umbrella. In this study, participants older than two years old were compared to older adults in terms of seropositivity.

17 Jun 2021

Rapid Point-of-Care Testing Using Screen-Printed Electrodes from Metrohm DropSens

Point-of-care (POC) testing with screen-printed electrodes allows rapid testing of populations for viral outbreaks – at affordable costs, without the need for trained specialists and/or complicated equipment.

From Metrohm Middle East FZC 11 Jun 2021

Nanozymes to the rescue - potential role in fighting COVID-19

Over the last few decades, researchers have developed artificial enzymes for many applications. Recently, they deployed nanomaterial-based enzyme mimetics or nanozymes in diagnosis and therapeutics. Nanozymes find applications in various biomedical applications, including antiviral agents and cancer therapy.

8 Jun 2021

High baseline levels of inflammatory cytokines linked to thrombotic events in patients with COVID-19

In a recent open-access paper published in the Journal of Clinical Medicine, researchers from Iran and Germany show that high baseline levels of inflammatory cytokines measured during admission put patients with coronavirus disease (COVID-19) at increased risk of developing coagulopathy, thrombotic events – and even death.

6 Jun 2021

Study compares Pfizer and Moderna mRNA vaccine-elicited response to SARS-CoV-2 variants

A new study has been published on the bioRxiv preprint server which focuses on the correlation between the vaccine-triggered Immunoglobulin G (IgG) levels and neutralization titers against SARS-CoV-2 variants. Further, neutralization activities against the variants (B.1.1.7, B.1.525, and B.1.351), using Pfizer or Moderna vaccine, sera were assessed.

3 Jun 2021

A novel multiplexed diagnostic approach for COVID-19

Researchers developed a platform for detecting the virus directly from a patient's sample as well as the immune response through antibodies such as IgG and IgM.

31 May 2021

A possible human-to-canine transmission of SARS-CoV-2

Now, researchers at the U.S. Centers for Disease Control and Prevention (CDC) identified a case of human to animal transmission when SARS-CoV-2 was detected in a healthy poodle dog living with four family members who had COVID-19.

18 May 2021

Antibodies generated by malaria cross-react with SARS-CoV-2

An international team of researchers has warned that individuals with acute malaria infection generate high levels of antibodies that cross-react with the viral spike protein of the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that causes coronavirus disease 2019 (COVID-19).

13 May 2021

Immunity developed by SARS-CoV-2 infection can protect against E484K variants, suggests study

A team of scientists from Japan has recently investigated the neutralizing potency of convalescent sera against currently circulating SARS-CoV-2 variants with multiple spike mutations.